HIF1A and pancreatic neoplasm: It has been demonstrated that high expression of HIF-1α can increase resistance of pancreatic tumor cells to the current first line chemotherapeutic gemcitabine and that knock down of HIF-1α combined with gemcitabine leads to significant synergistic effects [87,88].